Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, single-arm, Phase IIIb study to demonstrate the efficacy and safety of a single dose of the new L-praziquantel orally disintegrating tablets in children age 2 to 6 years infected with Schistosoma haematobium (urogenital schistosomiasis)

Next Previous
Trial Profile

Open-label, single-arm, Phase IIIb study to demonstrate the efficacy and safety of a single dose of the new L-praziquantel orally disintegrating tablets in children age 2 to 6 years infected with Schistosoma haematobium (urogenital schistosomiasis)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Praziquantel (Primary)
  • Indications Schistosomiasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co

Most Recent Events

  • 13 Jul 2020 Status changed from not yet recruiting to discontinued.
  • 18 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top